Mark Mintz
Known title: EVP, Chief Information OfficerCIK: 0002071546
Associated companies
Transaction History
| CRL | ▼ Sell | Tax Withholding | 64 | $12K | 5/31/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 305 | $55K | 5/30/2026 | View on chart |
| CRL | ▲ Buy | Grant | 2,534 | $458K | 5/29/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 47 | $7K | 5/27/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 64 | $10K | 5/26/2026 | View on chart |
| CRL | ▲ Buy | Grant | 1,797 | $0 | 1/30/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 655 | $139K | 1/30/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.